169
Views
6
CrossRef citations to date
0
Altmetric
Photo Essays

Homonymous Hemianopsia Due to Posterior Cortical Atrophy

, &
Pages 154-158 | Received 22 Dec 2016, Accepted 30 Dec 2016, Published online: 15 Feb 2017

References

  • Brazis PW, Lee AG, Graff-Radford N, Desai NP. Homonymous visual field defects in patients without corresponding structural lesions on neuroimaging. J Neuroophthalmol 2000;20:92–96.
  • Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol 1988;45:789–793.
  • Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Nick CF. Posterior cortical atrophy. Lancet Neurol 2012;11:170–178.
  • Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, Pritchard A, Lendon CL, Richardson AM, Varma A, Neary D, Mann D. Cognitive phenotypes in Alzheimer’s disease and genetic risk. Cortex 2007;43:835–845.
  • Zakzanis KK, Boulos MI. Posterior cortical atrophy. Neurologist 2001;7:341–349.
  • Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer’s type. Neurology 1995;45:68–74.
  • Renner JA, Burns JM, Hou CE, McKeel DW Jr, Storandt M, Morris JC. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology 2004;63:1175–1180.
  • Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook RJ, Knopman DS, Petersen RC. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168–1174.
  • Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook RJ, Knopman DS, Petersen RC. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168–1174.
  • Charles RF, Hillis AE. Posterior cortical atrophy. Behav Neurol 2005;16:15–23.
  • Mendez MF, Ghajarania M, Perryman KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer’s disease. Dement Geriatr Cogn Disord 2002;14:33–40.
  • Kas A, de Souza LC, Samri D, Bartolomeo P, Lacomblez L, Kalafat M, Migliaccio R, Thiebaut de Schotten M, Cohen L, Dubois B, Habert MO, Sarazin M. Neural correlates of cognitive impairment in posterior cortical atrophy. Brain 2011;134(Pt 5):1464–1478.
  • Vighetto A. Towards an earlier diagnosis of Alzheimer’s disease presenting with visuospatial disorders (posterior cortical atrophy). Rev Neurol (Paris) 2013;169:687–694.
  • Pelak VS, Smyth SF, Boyer PJ, Filley CM. Computerized visual field defects in posterior cortical atrophy. Neurology 2011;77:2119–2122.
  • Formaglio M, Krolak-Salmon P, Tilikete C, Bernard M, Croisile B, Vighetto A. Homonymous hemianopia and posterior cortical atrophy. Rev Neurol (Paris) 2009;165:256–262.
  • Harrison AR, Lee MS. The woman who needed a pet. Surv Ophthalmol 2006;51:592–955.
  • Kaeser PF, Ghika J, Borruat FX. Visual signs and symptoms in patients with the visual variant of Alzheimer disease. BMC Ophthalmol 2015;15:65.
  • Fletcher WA. Ophthalmological aspects of Alzheimer’s disease. Curr Opin Ophthalmol 1994;5:38–44.
  • Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement 2015;11:58–69.
  • Schmidtke K, Hull M, Talazko J. Posterior cortical atrophy: variant of Alzheimer’s disease? A case series with PET findings. J Neurol 2005;252:27–35.
  • Degenhardt EK, Witte MM, Case MG, Yu P, Henley DB, Hochstetler HM, D’Souza DN, Trzepacz PT. Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate alzheimer dementia. Psychosomatics 2016;57:208–216.
  • Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 2012;8:312–336.
  • Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1–42, total tau, and ptau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011;68:1137–1144.
  • Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl 2003;179:47–51.
  • Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA. Amyloid-beta(1–42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248–253.
  • Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2:605–613.
  • Lee AG, Martin CO. Neuro-ophthalmic findings in the visual variant of Alzheimer’s disease. Ophthalmology 2004;111:376–381.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.